

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/209419 A1

(51) International Patent Classification:

A61K 31/7072 (2006.01) *A61P 31/14* (2006.01)

A61K 31/7076 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2021/059504

(22) International Filing Date:

13 April 2021 (13.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20169480.9 14 April 2020 (14.04.2020) EP

(71) Applicant: JANSSEN SCIENCES IRELAND UN-
LIMITED COMPANY [IE/IE]; Barnahely Ringaskiddy,
Co Cork (IE).

(72) Inventors: JONCKERS, Tim, Hugo, Maria; c/o Janssen
Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE).
PAUWELS, Frederik; c/o Janssen Pharmaceutica NV
Turnhoutseweg 30, 2340 Beerse (BE). DEBING, Yannick;
c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340
Beerse (BE).

(74) Agent: PUREWAL, Savroop; Turnhoutseweg 30, 2340
Beerse (BE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

(57) Abstract: The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

WO 2021/209419 A1